Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carcinoembryonic antigen RNA-pulsed dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- Duke University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
**Carcinoembryonic antigen RNA-pulsed dendritic cell vaccine** is an individualized autologous dendritic-cell cancer vaccine in which patient-derived dendritic cells are loaded with messenger RNA encoding carcinoembryonic antigen. The antigen-presenting cells are administered intravenously to induce carcinoembryonic antigen-specific cellular immune responses, including cytotoxic T-cell activity against carcinoembryonic antigen-expressing tumor cells. It was evaluated in Duke University-sponsored early clinical studies in metastatic carcinoembryonic antigen-expressing adenocarcinoma and after complete resection of colorectal cancer liver metastases. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/carcinoembryonic-antigen-rna-pulsed-dc-cancer-vaccine))
- Other names
- carcinoembryonic antigen RNA-pulsed dendritic cell cancer vaccinecarcinoembryonic antigen RNA-pulsed DC cancer vaccineCEA RNA-pulsed DC cancer vaccineCEA RNA-pulsed dendritic cell cancer vaccineCEARNAVAC
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on carcinoembryonic antigen RNA-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carcinoembryonic antigen RNA-pulsed dendritic cell vaccine.